Valuation: RetinalGenix Technologies Inc.

Market Cap 75.19M 68.57M 63.4M 57.22M 108M 7.03B 112M 766M 303M 3.79B 282M 276M 11.97B P/E 2024
-21.8x
P/E 2025 -24.5x
Enterprise Value 75.72M 69.05M 63.85M 57.62M 109M 7.08B 113M 771M 305M 3.82B 284M 278M 12.06B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
33.9%
Yield 2024 *
-
Yield 2025 -
11-18 RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
08-15 RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-21 RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-16 RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-15 RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt CI
03-27 Retinalgenix Technologies Inc. Announces Resignation of Michael Cory Zwerling as Chief Financial Officer, Effective March 22, 2026 CI
01-14 RetinalGenix Technologies Inc. Reports on Its Science and Mission in Light of New AI-Driven Retinal Mapping Study CI
12-09 RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Chief Financial Officer, Effective January 1, 2026 CI
12-09 RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Interim Chief Operating Officer, Effective January 1, 2026 CI
11-15 RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
01/10/25 RetinalGenix Technologies Inc. and RGEN Inc. Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases CI
01/10/25 RetinalGenix and RGEN Clinical Genotyping Lab partner to advance early disease detection RE
20/08/25 RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day-0.25%
3 months-0.25%
6 months-0.25%
Current year+24.69%
Current year 3.55
Extreme 3.55
4
1 year 3.55
Extreme 3.55
4
3 years 0.25
Extreme 0.25
6.36
5 years 0.25
Extreme 0.25
20
10 years 0.25
Extreme 0.25
20
Manager TitleAgeSince
Chief Executive Officer 73 01/12/2018
Director TitleAgeSince
Chairman 73 01/12/2018
Director/Board Member 97 01/04/2019
Director/Board Member 58 26/07/2022
Change 5-day change 1-year change 3-year change Capi.($)
-11.25%-.--%+24.69%+29.13% 75.19M
+0.19%-2.90%+56.40%+69.15% 65.45B
-1.07%-4.08%+6.65%+88.68% 58.93B
+0.27%+0.93%+26.93%+88.19% 55.21B
-0.48%-2.66%+14.45%+115.51% 46.1B
-0.12%-3.80%+19.93%+27.05% 42.49B
-2.58%+0.24%+18.54%+41.28% 35.56B
+1.42%-11.56%+128.68%+642.25% 34.57B
-0.01%-0.93%+78.73%+59.32% 32.46B
+0.65%+1.36%-41.21%+386.11% 26.28B
Average -0.19%-2.78%+33.38%+154.67% 40B
Weighted average by Cap. -0.21%-2.82%+34.41%+143.13%

Financials

2024 2025
Net sales - -
Net income -4.32M -3.94M -3.64M -3.29M -6.19M -404M -6.44M -44M -17.39M -218M -16.21M -15.87M -688M -2.43M -2.21M -2.05M -1.85M -3.48M -227M -3.62M -24.73M -9.78M -122M -9.11M -8.92M -387M
Net Debt 518K 473K 437K 394K 743K 48.43M 772K 5.28M 2.09M 26.14M 1.94M 1.9M 82.54M 530K 483K 447K 403K 760K 49.53M 790K 5.4M 2.13M 26.73M 1.99M 1.95M 84.41M
Projected Income Statement - Annual - RetinalGenix Technologies Inc.
Logo RetinalGenix Technologies Inc.
RetinalGenix Technologies Inc. is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. The Company's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. It is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. RTGN Stock